These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 18308215)

  • 41. EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer.
    Yamamoto K; Shimada S; Hirota M; Yagi Y; Matsuda M; Baba H
    Int J Oncol; 2005 Nov; 27(5):1321-8. PubMed ID: 16211228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
    Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
    Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
    JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma.
    Takahashi H; Ogawa H; Ohigashi H; Gotoh K; Yamada T; Ohue M; Miyashiro I; Noura S; Kishi K; Motoori M; Shingai T; Nakamura S; Nishiyama K; Yano M; Ishikawa O
    Surgery; 2011 Sep; 150(3):547-56. PubMed ID: 21621236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant therapies in extended pancreatectomy for ductal adenocarcinoma of the pancreas.
    Ishikawa O; Ohigashi H; Sasaki Y; Masao K; Kabuto T; Furukawa H; Imaoka S
    Hepatogastroenterology; 1998; 45(21):644-50. PubMed ID: 9684110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postoperative cytology for drained fluid from the pancreatic bed after "curative" resection of pancreatic cancers: does it predict both the patient's prognosis and the site of cancer recurrence?
    Ishikawa O; Wada H; Ohigashi H; Doki Y; Yokoyama S; Noura S; Yamada T; Sasaki Y; Imaoka S; Kasugai T; Matsunaga T; Takenaka A; Nakaizumi A
    Ann Surg; 2003 Jul; 238(1):103-10. PubMed ID: 12832972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
    Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
    Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma.
    Klautke G; Foitzik T; Ludwig K; Ketterer P; Klar E; Fietkau R
    Strahlenther Onkol; 2004 Nov; 180(11):695-700. PubMed ID: 15549187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
    Turrini O; Viret F; Moureau-Zabotto L; Guiramand J; Moutardier V; Lelong B; de Chaisemartin C; Giovannini M; Delpero JR
    Oncology; 2009; 76(6):413-9. PubMed ID: 19407474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
    Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
    Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer.
    Strobel O; Berens V; Hinz U; Hartwig W; Hackert T; Bergmann F; Debus J; Jäger D; Büchler MW; Werner J
    Surgery; 2012 Sep; 152(3 Suppl 1):S33-42. PubMed ID: 22770956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
    Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
    Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neo adjuvant chemo-radiotherapy and rectal cancer: can India follow the West?
    Bansal V; Bhutani R; Doval D; Kumar K; Pande P; Kumar G
    J Cancer Res Ther; 2012; 8(2):209-14. PubMed ID: 22842363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
    Mornex F; Girard N; Delpero JR; Partensky C
    Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Neoadjuvant and adjuvant therapy of ductal pancreatic carcinoma].
    Hohenberger W; Kastl S
    Zentralbl Chir; 2000; 125(4):348-55. PubMed ID: 10829315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.
    Leers JM; Ayazi S; Hagen JA; Terterov S; Klipfel N; Oezcelik A; Abate E; Lipham JC; DeMeester SR; Banki F; DeMeester TR
    J Am Coll Surg; 2009 Apr; 208(4):553-6. PubMed ID: 19476789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Thomas PR
    Hepatogastroenterology; 1998; 45(21):610-2. PubMed ID: 9684105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of borderline resectable pancreatic adenocarcinoma.
    Jia Y; Wang TJ; Allendorf J; Saif MW
    JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.